Trinity Biotech plc (TRIB:NASDAQ) closed at $7.93 on October 15, 2026, up 19.97% on the day. The stock trades 84.9% below its 52-week high of $52.50 and 58.3% above its 52-week low of $5.01. Trinity Biotech plc is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
| 5D | 1M | 3M | 6M |
|---|---|---|---|
| +20.88% | +12.80% | -22.25% | -64.28% |
In 251 trading sessions since October 15, 2025, TRIB closed higher on 81 days (32%). Its best day was December 23, 2025 (+43.82%) and its worst was June 23, 2026 (-37.93%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 6 times.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and Hb variants for the detection of Heamoglobinapothies. It also develops, manufactures, and distributes products in the immunofluorescence, enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, as well as haemolytic anaemia. In addition, the company offers Uni-Gold HIV, a POC diagnostic test, which is carried out in the presence of the patient to diagnose the presence of HIV antibodies. Further, it provides emergency medicine diagnostic tests; and sells raw materia...
Find more stocks like TRIB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.